Drainage Seton With Flap Versus EAS Preserving Seton in Treatment of Transsphincteric Anal Fistula

Overview

Patients with high trans-sphincteric anal fistula will be randomized to one of two equal group: group 1 will have drainage seton with mucosal advancement flap and group 2 will undergo external anal sphincter sparing seton

Full Title of Study: “Drainage Seton Around the External Anal Sphincter With Mucosal Advancement Flap Versus External Anal Sphincter Preserving Seton in Treatment of Trans-sphincteric Anal Fistula”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: April 30, 2018

Interventions

  • Procedure: Drainage seton with flap
    • Seton is placed around the external sphincter then mucosal advancement flap will be constructed
  • Procedure: EAS sparing seton
    • Rerouting of the seton around the internal sphincter only sparing the external sphincter

Arms, Groups and Cohorts

  • Experimental: Drainage seton with flap
    • Drainage seton will be put around the external anal sphincter with mucosal advancement flap
  • Experimental: EAS sparing seton
    • Rerouting of the seton around the internal anal sphincter sparing the external sphincter will be done

Clinical Trial Outcome Measures

Primary Measures

  • fecal incontinence
    • Time Frame: 12 months after surgery
    • Number of patients who develop fecal incontinence as assessed by Wexner Incontinence score

Participating in This Clinical Trial

Inclusion Criteria

  • Patients suffering from high trans-sphincteric anal fistula Exclusion Criteria:

  • Acute sepsis. – Specific cause of fistula e.g. Crohn's disease – Strictured anorectum. – Any degree of incontinence – Recurrent anal fistula. – Low anal fistula. – Previous anorectal surgery.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Mansoura University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Sameh Emile, Principal investigator – Mansoura University
  • Overall Official(s)
    • Sameh Emile, M.D., Principal Investigator, Mansoura University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.